Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-01-15
2008-01-15
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S338000, C546S113000, C546S276700
Reexamination Certificate
active
10810999
ABSTRACT:
Compounds of formula Ipharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.
REFERENCES:
patent: 5071999 (1991-12-01), Schenke et al.
patent: 5382584 (1995-01-01), Balasubramanian
patent: 5472958 (1995-12-01), Gunn et al.
patent: 5478939 (1995-12-01), Trybulski et al.
patent: 5773912 (1998-06-01), Saeki et al.
patent: 5914328 (1999-06-01), Lin et al.
patent: 5948793 (1999-09-01), Abreo et al.
patent: 0 324 543 (1989-07-01), None
patent: 0 400 661 (1990-12-01), None
patent: 0 603 887 (1994-09-01), None
patent: 0 345 808 (1995-01-01), None
patent: 94/08922 (1994-04-01), None
patent: 95/23152 (1995-08-01), None
patent: 96/06093 (1996-02-01), None
patent: 96/31475 (1996-10-01), None
patent: 97/05139 (1997-02-01), None
patent: 97/17961 (1997-05-01), None
patent: 99/21834 (1999-05-01), None
patent: 99/32117 (1999-07-01), None
patent: 99/51602 (1999-10-01), None
patent: 00/34284 (2000-06-01), None
patent: 00/44755 (2000-08-01), None
patent: 00/66586 (2000-11-01), None
patent: 00/71534 (2000-11-01), None
patent: 01/44243 (2001-06-01), None
Arneric et al., “Cholingeric channel modulators as a novel therapeutic strategy for alzheimer's disease,” Exp. Opin. Invest. Drugs 5(1):79-100 (1996).
Arneric, et al., “Neuronal Nicotinic Acetylcholine Receptors,” Psychopharmacology: The fourth Generation of Progress 95-109 (1995).
Barlocco et al., J. Med. Chem. 41:674-681 (1998).
Benowitz, et al., “Pharmacokinetics, metabolism, and pharmacodynamics of nicotine,” Nicotine Psychopharmacology 112-157 (1990).
Berge, et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Sciences 66(1):1-19 (1977).
Brehm et al., “Glycine antagonists, synthesis, structure, and biological effects of some bicyclic 5-isoxazolol zwitterions,” J. Med. Chem. 269:224-229 (1986).
Chem Pharm Bull. 6:408-411 (1958).
Cherny, “Opioid Analgesics,” Drug 51(5):713-737 (1996).
Cope et al., “Synthesis of D-and L-2,6-diheterobicyclo [3.3.0]octanes,” JACS 78:5916-5920 (1956).
Corey, et al., “A synthetic method for formyl-ehtynyl conversion (RCHO-RC=CH or CR),” Tetrahedron Letters 36:3769-3772 (1972).
Davidson, et al., “Cholinergic Agonists in alzheimer's Disease Patients,” Current Research in Alzheimer Therapy 333-336 (1988).
Decker et al., “Therapeutic potential of Neuronal Nicotinic Acetylcholine Receptor Agonists As Novel Analgesics,” Biochemical Pharmacology 58:917-923 (1999).
Dormoy, “Synthese Industrielle en serie ellipticine,” Tetrahedron 49(14):2885-2914 (1993).
Dray et al., “New pharmacological strategies for pain relief,” Annu. Rev. Pharmacol. Toxicol 36:253-80 (1996).
Dray, et al., Trends in Pharmacol. Sci. 15:190-197 (1994).
Gribble, et al., “Regioselective ortho lithiation of halopyridines,” Tetrahedron letters 21:4137-4140 (1980).
Hands, et al., “A convenient method for the preparation of 5-,6 and 7-azaindoles and their derivates,” Synthesis 877-882 (1996).
IUPAC, Pure and Applied Chemistry 45:13-30, 1976.
Jacquet et al., Tetrahedron Letters 32(12):1565-1568 (1991).
Knight et al., “6-Hydroxypiperidinecarboxylates: additions to the chiral pool from bakers' yeast reduction of beta-ketopiperidinecarboxylates,” J. Chem Soc. Perkins Trans. 1:3673-3683 (1998).
Korczyn, “Parkinson's Disease” Psychopharmacology: The Fourth Generation of Progress 126:1479-1484, 1995.
Lazar, et al., “Saturated heterocycles, Part 172. Synthesis of 2,6-disubstituted-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine derivates,” J. Heterocyclic Chem. 27:1885-1892 (1990).
Linstrom, “Nicotinic Acetylcholine Receptors in Health and disease,” Molecular Neurobiology 15:193-222 (1997).
Lloyd et al, “The potential of subype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents,” Life Sciences 62(17/18):1601-1606 (1998).
Numata, et al., “General synthetic method for naphthyridines and their n-oxides containing isoquinolinic nitrogen,” Synthesis 2:306-311 (1999).
Organic Mass Spectrometry 19(9):459-450 (1984).
Padwa, et al., Organic Synthesis 67:133-140 (1988).
Pebreza et al., Molecuar Pharmacology 39:9-12 (1990).
Paste et al., Methods in Cell Biology XIV:33-71 (1976).
Reimschussel, et al., “Studies on new derivatives of caprolactam,” Journal of Organic Chemistry 34(4):959-963 (1969).
Ronn, et al., “Palladium(II)-Catalyzed Cyclization Using Molecual Oxygen as reoxidant,” Tetrahedron Letters 36(42):7749-7752 (1995).
Roth, et al, “Biochemical Pharmacology of Midbrain dopamine Neurons,” Psychopharmacology: The Fourth Generation of Progress 227-243 (1995).
Salin-Pascual, et al., “Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression,” J. Clin. Psychiatry 57:387-389 (1996).
Clayton, et al., “A total synthesis of (±)-Epibatidine,” Tetrahedron Letters 36(46):7493-7496 (1993).
Sirisoma, et al., Alpha-Iodocyloalkenones: synthesis of (±)-Epibatidine,: Tetrahedron Letters 39:2059-2062 (1998).
Wagaw, et al., “The synthesis of aminopyridines:A method employing palladium-catalyzed carbon-nitrogen bond formation,” J. Org. Chem. 61:7240-4241 (1996).
Williams et al, “Beyond the tobacco debate: dissecting out the therapeutic potential of nicotine,” Exp. Opin. Invest. Drugs 5(8):1035-1045 (1996).
Williams, et al., J. Med. Chem. 42(9):1481-1500 (1999).
Wittenberger, et al., “Dialkyltin Oxide mediated addition of trimethylsilyl azide to nitriles. A novel preparation of 5-substituted tetrazoles,” J. Org. Chem. 58:4139-4141 (1993).
Ghelardini et al., “Antinociceptive profile of the new nicotinic agonists DBO-83,” Drug Development Research 40:251-258 (1997).
Basha Anwer
Bunnelle William H.
Daanen Jerome F.
Ji Jianguo
Pace Jennifer M.
Abbott Laboratories
Chen Portia
Coleman Brenda
LandOfFree
Diazabicyclic central nervous system active agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diazabicyclic central nervous system active agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diazabicyclic central nervous system active agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3934994